📰 Pipeline Progress News
Pipeline Progress News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pipeline Progress. Real-time updates on events, politics, business and more.
November 15, 2023
Operator: Greetings and welcome to the Arcturus Therapeutics Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
November 2, 2023
– NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR – – mNPM1 final efficacy data from the Phase 1 portion of AUGMENT-101...
August 8, 2023
Operator: Greetings, and welcome to Arcturus Therapeutics Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
March 30, 2023
Operator: Greetings, and welcome to the Arcturus Therapeutics Fourth Quarter 2022 Financial Update and Pipeline Progress Call. At this time, all participants are in a listen-only mode.
February 28, 2023
/PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies,...
November 3, 2022
/PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies,...
August 18, 2022
Investegate announcements from LumiraDx Inc, LumiraDx Reports Second Quarter 2022 Results
August 10, 2022
Acrturus Therapeutics Holdings Inc. Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Joseph Payne - President and Chief Executive Officer Andrew Sassine -...
August 8, 2022
/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an...
May 9, 2022
– Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA filings in 2023 – –...